Complications of cyclophosphamide therapy

European Archives of Oto-Rhino-Laryngology

Volumn 254, Issue 2, 1997, Pages 65-72

  Langford, C A ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Autoimmune disease; Cyclophosphamide; Toxicity; Vasculitis; Wegener's granulomatosis

Indexed keywords

CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT;

ALOPECIA; BONE MARROW SUPPRESSION; CANCER; CARCINOGENICITY; CARDIOTOXICITY; GONAD DYSFUNCTION; HEAD AND NECK CANCER; HUMAN; INFLAMMATORY DISEASE; LUNG TOXICITY; NAUSEA; NEPHROTOXICITY; PRIORITY JOURNAL; REVIEW; TERATOGENICITY; VOMITING; WEGENER GRANULOMATOSIS;

BONE MARROW; CLINICAL PROTOCOLS; CYCLOPHOSPHAMIDE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; LUNG; NEOPLASMS; WEGENER GRANULOMATOSIS;

EID: 0030889409     PISSN: 09374477     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01526181     Document Type: Review

References (64)

1. Ataya K, Valeriote FA, Ramahi-Ataya A (1989) Effects of cyclophosphamide on the immature rat ovary. Cancer Res 49 : 1660-1664
2. Austin HA, Klippel JH, Balow JE, LeRiche NGH, Steinberg AD, Plotz PH, Decker JL (1986) Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs. N Engl J Med 314 : 614-619
3. Bagley CM, Bostick FW, DeVita VT (1973) Clinical pharmacology of cyclophosphamide. Cancer Res 33 : 226-233
4. Baltus JAM, Boersma JW, Hartman AP, Vanderbroucke JP (1983) The occurrence of malignancies in patients with rheumatoid arthritis treated with cyclophosphamide: a controlled retrospective study. Ann Rheum Dis 42 : 368-373
5. Bermas BL, Hill JA (1995) Effects of immunosuppressive drugs during pregnancy. Arthritis Rheum 38 : 1722-1732
6. Boumpas DT, Austin HA, Vaughn EM, Klippel JH, Steinberg AD, Yarboro CH, Balow JE (1992) Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340 : 741-745
7. Boumpas DT, Austin HA, Vaughan EM, Yarboro CH, Klippel JH, Balow JE (1993) Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 119 : 366-369
8. Brock N (1967) Pharmacologic characterization of cyclophosphamide (NSA-26271) and cyclophosphamide metabolites. Cancer Chemother Rep 51 : 315-325
9. Buckner CD, Rudolph RH, Fefer A, Clift RA, Epstein RB, Funk DD, Neiman PE, Slichter SJ, Storb R, Thomas ED (1972) High-dose cyclophosphamide therapy for malignant disease: toxicity, tumor response, and the effects of stored autologous marrow. Cancer 29 : 357-365
10. Burke DA, Stoddart JC, Ward MK, Simpson CGB (1982) Fatal pulmonary fibrosis occurring during treatment with cyclophosphamide. BMJ 285 : 696
11. Casciato DA, Scott JL (1979) Acute leukemia following prolonged cytotoxic agent therapy. Medicine 58 : 32-47
12. Chapman RM (1992) Gonadal toxicity and teratogencity. In: Perry MC (ed) The chemotherapy source book. Williams and Wilkins, Baltimore, pp 710-753
13. Chapman RM, Sutcliffe SB, Malpas JS (1979) Cytotoxic-induced ovarian failure in women with Hodgkin's disease. JAMA 242 : 1877-1881
14. Colvin M, Chabner BA (1990) Alkylating agents. In: Chabner BA, Collins JM (eds) Cancer chemotherapy: principles and practice. Lippincott, Philadelphia, pp 277-313
15. Colvin M, Hilton J (1981) Pharmacology of cyclophosphamide and metabolites. Cancer Treat Rep 65 [Suppl 3] : 89-95
16. Cooper JAD, White DA, Matthay RA (1986) Drug-induced pulmonary disease. Am Rev Respir Dis 133 : 321-340
17. Cox PJ (1979) Cyclophosphamide cystitis - identification of acrolein as the causative agent. Biochem Pharmacol 28 : 2045-2049
18. DeFronzo Ra, Colvin OM; Braine H, Robertson GL, Davis PJ (1974) Cyclophosphamide and the kidney. Cancer 33 : 483-491
19. Fauci AS, Young KR (1993) Immunoregulatory agents. In: Kelley WN, Harris ED, Ruddy S, Sledge CB (eds) Textbook of rheumatology, 4th edn. Saunders, Philadelphia, pp 797-821
20. Fauci AS, Dale DC, Balow JE (1976) Glucocorticoid therapy: mechanisms of action and clinical consideratons. Ann Intern Med 84 : 304-315
21. Fischer DS (1989) Cancer chemotherapy. In: Lee KJ (ed) Textbook of otolaryngology and head and neck surgery. Elsevier, New York, pp 902-914
22. Fisher RI, Oken MM (1995) Clinical practice guidelines: non-Hodgkin's lymphomas. Cleve Clin J Med 62 [Suppl 1] : 6-42
23. Fox DA, McCune WJ (1994) Immunosuppressive drug therapy of systemic lupus erythematosus. Rheum Dis Clin North Am 20 : 265-299
24. Fraiser LH, Kanekal S, Kehrer JP (1991) Cyclophosphamide toxicity: characterizing and avoiding the problem. Drugs 42 : 781-795
25. Ginsberg SJ, Comis RL (1984) The pulmonary toxicity of antineoplastic agents. In: Perry MC, Yarbro JW (eds) Toxicity of chemotherapy. Grune and Stratton, Orlando, pp 227-268
26. Godeau B, Coutant-Perronne V, Huong DLT, Guillevin L, Magadur G, Bandt M de, Dellion S, Rossert J, Rostoker G, Piette J-C, Schaeffer A (1994) Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases. J Rheumatol 21 : 246-251
27. Greenberg LH, Tanaka KR (1964) Congenital abnormalities probably induced by cyclophosphamide. JAMA 188 : 423-426
28. Grunwald HW, Rosner F (1979) Acute leukemia and immunosuppressive drug use: review of patients undergoing immunosuppressive therapy for non-neoplastic disease. Ann Intern Med 139 : 461-466
29. Harmenberg J, Hoglund M, Hellstrom-Lindberg E (1994) G-and GM-CSF in oncology and oncological haematology. Eur J Haematol 52 : 1-28
30. Haynes BF (1992) Glucocorticosteroid therapy. In: Wyngaarden JB, Smith LH, Bennett JC (eds) Cecil textbook of medicine, 19th edn. Saunders, Philadelphia, pp 104-108
31. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, Rottem M, Fauci AS (1992) Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 116 : 488-498
32. Jarrousse B, Guillevin L, Bindi P, Hachulla E, Leclerc P, Nilson B, Remy P, Rossert J, Jacquot C (1993) Increased risk of Pneumocystis carinii pneumonia in patients with Wegener's granulomatosis. Clin Exp Rheumatol 11 : 615-621
33. Kahl LE (1994) Herpes zoster infections in systemic lupus erythematosus: risk factors and outcome. J Rheumatol 21 : 84-86
34. Kantarjian HM, Keating MJ (1987) Therapy-related leukemia and myelodysplastic syndrome. Semin Oncol 14 : 435-443
35. Khandekar JD (1991) Chemotherapy of head and neck cancer. In: Ballenger JJ (ed) Diseases of the nose, throat, ear, head, and neck. Lea and Febiger, Philadelphia, pp 753-766
36. Koren G, Beatty K, Seto A, Einarson TR, Lishner M (1992) The effects of impaired liver function on the elimination of antineoplastic agents. Ann Pharmacother 26 : 363-371
37. Koyama H, Wada T, Nishizawa Y, Iwanaga T, Aoki Y, Terasawa T, Kosaki G, Yamamoto T, Wada A (1977) Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer 39 : 1403-1409
38. Langford CA, McCallum RM (1995) Idiopathic vasculitis. In: Belch JJF, Zurier RB (eds) Connective tissue diseases. Chapman and Hall, London, pp 179-217
39. Langford CA, Sneller MC, Hallahan C, Hoffman GS, Kammerer WA, Talar-Williams C, Fauci AS, Lebovics RS (1995) Clinical features and therapeutic management of subglottic stenosis in patients with Wegener's granulomatosis. Arthritis Rheum [Suppl] 38 : S390
40. Mills BA, Roberts RW (1979) Cyclophosphamide-induced cardiomyopathy: a report of 2 cases and review of the English literature. Cancer 43 : 2223-2226
41. Mitchell EP, Schein PS (1992) Gastrointestinal toxicity of chemotherapeutic agents. In: Perry MC (ed) The chemotherapy source book. Williams and Wilkins, Baltimore, pp 620-634
42. Morgan MC, Matteson E, Dunne R, Brown M, Fox DA, McCune WJ (1990) Complication of intravenous cyclophosphamide: association of infections with high doses of prednisone in lupus patients. Arthritis Rheum 33 [Suppl 5] : R27
43. Mouridsen HT, Jacobsen E (1975) Pharmacokinetics of cyclophosphamide in renal failure. Acta Pharmacol Toxicol 36 : 409-414
44. Newell DR, Gore ME (1991) Toxicity of alkylating agents: clinical characteristics and pharmacokinetic determinants. In: Powis G, Hacker MP (eds) The toxicity of anticancer drugs. Pergamon, New York, pp 44-62
45. Patel JM (1990) Metabolism and pulmonary toxicity of cyclophosphamide. Pharmacol Ther 47 : 137-146
46. Pedersen-Bjergaard J, Ersboll J, Sorensen HM, Keiding N, Larsen SO, Philip P, Larsen MS, Schultz H, Nissen NI (1985) Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Ann Intern Med 103 : 195-200
47. Plotz PH, Klippel JH, Decker JL, Grauman D, Wolff B, Brown BC, Rutt G (1979) Bladder complications in patients receiving cyclophosphamide for systemic lupus erythematosus or rheumatoid arthritis. Ann Intern Med 91 : 221-223
48. Porges AJ, Beattie SL, Ritchlin C, Kimberly RP, Christian CL (1992) Patients with systemic lupus erythematosus at risk for Pneumocystis carinii pneumonia. J Rheumatol 19 : 1191-1194
49. Radis CD, Kahl LE, Baker GL, Wasko MCM, Cash JM, Gallatin A, Stolzer BL, Agarwal AK, Medsger TA, Kwoh CK (1995) Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis: a 20-year follow-up study. Arthritis Rheum 38 : 1120-1127
50. Roubenoff R, Hoyt J, Petri M, Hochberg MC, Hellmann DB (1988) Effects of antiinflammatory and immunosuppressive drugs on pregnancy and fertility. Semin Arthritis Rheum 18 : 88-110
51. Santos GW, Sensenbrenner LL, Burke PJ, Colvin M, Owens AH, Bias WB, Slavin RE (1971) Marrow transplantation in man following cyclophsophamide. Transplant Proc 3 : 400-404
52. Sen RP, Walsh TE, Fisher W, Brock N (1991) Pulmonary complications of combination therapy with cyclophosphamide and prednisone. Chest 99 : 143-146
53. Shepherd JD, Pringle LE, Barnett MJ, Klingemann H-G, Reece DE, Phillips GL (1991) Mesna versus hyperhydration for the prevention of cyclophosphamide-induced hemorrhagic cystitis in bone marrow transplantation. J Clin Oncol 9 : 2016-2020
54. Sneller MC, Huffman GS, Talar-Williams C, Kerr GS, Hallahan CW, Fauci AS (1995) An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone. Arthritis Rheum 38 : 608-613
55. Spector JI, Zimbler H, Ross JS (1979) Early-onset cyclophosphamide-induced interstitial pneumonitis. JAMA 242 : 2852-2854
56. Steele TH, Serpick AA, Block JB (1973) Antidiuretic response to cyclophosphamide in man. J Pharmacol Exp Ther 185 : 245-253
57. Stewart KA, Mazanec DJ (1992) Pulse intravenous cyclophosphamide for kidney disease in relapsing polychondritis. J Rheumatol 19 : 498-500
58. Stillwell TJ, Benson RC (1988) Cyclophosphamide-induced hemorrhagic cystitis. Cancer 61 : 451-457
59. Struck RF, Alberts DS, Home K, Phillips JG, Peng Y-M, Roe DJ (1987) Plasma pharmacokinetics of cyclophosphamide and its cytotoxic metabolites after intravenous versus oral administration in a randomized, crossover trial. Cancer Res 47 : 2723-2726
60. Talar-Williams C, Hijazi TM, Walther MM, Linehan WM, Hallahan CW, Lubensky I, Kerr GS, Hoffman GS, Fauci AS, Sneller MC (1996) Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 124 : 477-484
61. Tokaz LK, Von Hoff DD (1984) The cardiotoxicity of the anticancer drugs. In: Perry MC, Yarbro JW (eds) Toxicity of chemotherapy. Grune and Stratton, Orlando, pp 199-226
62. Toledo TM, Harper RC, Moser RH (1971) Fetal effects during cyclophosphamide and irradiation therapy. Ann Intern Med 74 : 87-91
63. Trasler JM, Hales BF, Robaire B (1985) Paternal cyclophosphamide treatment of rats causes fetal loss and malformations without affecting male fertility. Nature 316 : 144-146
64. Zemlickis D, Lishner M, Erlich R, Koren G (1993) Teratogenicity and carinogenicity in a twin exposed in utero to cyclophosphamide. Teratog Carcinog Mutagen 13 : 139-143